Serum biomarkers of spontaneous intracerebral hemorrhage induced secondary brain injury

Abstract Intracerebral hemorrhage (ICH) is a devastating form of stroke associated with a high rate of morbidity and mortality. It is now believed that much of this damage occurs in the subacute period following the initial insult via a cascade of complex pathophysiologic pathways that continues to...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the neurological sciences 2012-10, Vol.321 (1), p.1-10
Main Authors: Brunswick, Andrew S, Hwang, Brian Y, Appelboom, Geoffrey, Hwang, Richard Y, Piazza, Matthew A, Connolly, E. Sander
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Biomarker
Biomarkers - blood
Blood brain barrier
Brain Injuries - blood
Brain Injuries - etiology
Cerebral edema
Cerebral Hemorrhage - complications
Humans
Indexing in process
Injuries of the nervous system and the skull. Diseases due to physical agents
Intracerebral hemorrhage
Medical sciences
Neuroinflammation
Neurology
Secondary brain injury
Stroke management
Traumas. Diseases due to physical agents
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Intracerebral hemorrhage (ICH) is a devastating form of stroke associated with a high rate of morbidity and mortality. It is now believed that much of this damage occurs in the subacute period following the initial insult via a cascade of complex pathophysiologic pathways that continues to be investigated. Increased levels of certain serum proteins have been identified as biomarkers that may reflect or directly participate in the inflammation, blood brain barrier disruption, endothelial dysfunction, and neuronal and glial toxicity that occur during this secondary period of cerebral injury. Some of these biomarkers have the potential to serve as therapeutic targets or surrogate endpoints for future research or clinical trials. Others may someday augment current clinical techniques in diagnosis, risk-stratification, prognostication, treatment decision and measurement of therapeutic efficacy. While much work remains to be done, biomarkers show significant potential to expand clinical options and improve clinical management, thereby reducing mortality and improving functional outcomes in ICH patients.
ISSN:0022-510X
1878-5883
DOI:10.1016/j.jns.2012.06.008